Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo.

Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, Raitano AB, Jia XC, Gudas JM, Kanner SB, Jakobovits A.

Cancer Res. 2007 Jun 15;67(12):5798-805.

2.

Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB.

Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M.

Clin Cancer Res. 2003 Aug 1;9(8):3167-75.

3.

Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma.

Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M.

Cancer Res. 2002 Sep 1;62(17):5106-14.

4.

Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.

Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M.

Am J Pathol. 2002 Jul;161(1):125-34.

6.
7.

Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide.

Jeffy BD, Schultz EU, Selmin O, Gudas JM, Bowden GT, Romagnolo D.

Mol Carcinog. 1999 Oct;26(2):100-18.

PMID:
10506754
8.

Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers.

Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO, Coats S.

Mol Cell Biol. 1999 Jan;19(1):612-22.

9.

P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers.

Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, Ikeda K, Tsurutani J, Ikuno N, Omagari K, Mizuta Y, Soda H, Gudas JM, Kohno S.

Jpn J Cancer Res. 1997 Aug;88(8):738-42.

10.

Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.

Gudas JM, Nguyen H, Li T, Sadzewicz L, Robey R, Wosikowski K, Cowan KH.

Carcinogenesis. 1996 Jul;17(7):1417-27.

PMID:
8706243
11.

Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.

Gudas JM, Li T, Nguyen H, Jensen D, Rauscher FJ 3rd, Cowan KH.

Cell Growth Differ. 1996 Jun;7(6):717-23.

12.

Normal p53 status and function despite the development of drug resistance in human breast cancer cells.

Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE.

Cell Growth Differ. 1995 Nov;6(11):1395-403.

13.

Hormone-dependent regulation of BRCA1 in human breast cancer cells.

Gudas JM, Nguyen H, Li T, Cowan KH.

Cancer Res. 1995 Oct 15;55(20):4561-5.

14.
15.

Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line.

Goldsmith ME, Gudas JM, Schneider E, Cowan KH.

J Biol Chem. 1995 Jan 27;270(4):1894-8.

16.

Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.

Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH.

Clin Cancer Res. 1995 Jan;1(1):71-80.

17.

Serum-responsive expression from the murine thymidine kinase promoter is specifically disrupted in a transformed cell line.

Bradley DW, Fridovich-Keil JL, Gudas JM, Pardee AB.

Cell Growth Differ. 1994 Oct;5(10):1137-43.

18.

Utilization of multiple polyadenylation signals in the human RHOA protooncogene.

Moscow JA, He R, Gudas JM, Cowan KH.

Gene. 1994 Jul 8;144(2):229-36.

PMID:
8039707
19.

Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells.

Gudas JM, Oka M, Diella F, Trepel J, Cowan KH.

Cell Growth Differ. 1994 Mar;5(3):295-304.

20.

DNA sequences required for serum-responsive regulation of expression from the mouse thymidine kinase promoter.

Fridovich-Keil JL, Markell PJ, Gudas JM, Pardee AB.

Cell Growth Differ. 1993 Aug;4(8):679-87.

21.
22.

Characterization of the murine thymidine kinase-encoding gene and analysis of transcription start point heterogeneity.

Gudas JM, Fridovich-Keil JL, Datta MW, Bryan J, Pardee AB.

Gene. 1992 Sep 10;118(2):205-16.

PMID:
1511894
23.

Transcription initiation and temporal expression of thymidine kinase mRNA in Chinese hamster cells.

Gudas JM.

Biochem Biophys Res Commun. 1992 Apr 30;184(2):908-14.

PMID:
1575759
24.

Improved expression vectors for eukaryotic promoter/enhancer studies.

Fridovich-Keil JL, Gudas JM, Bryan IB, Pardee AB.

Biotechniques. 1991 Nov;11(5):572-9.

PMID:
1725108
25.

Growth-responsive expression from the murine thymidine kinase promoter: genetic analysis of DNA sequences.

Fridovich-Keil JL, Gudas JM, Dou QP, Bouvard I, Pardee AB.

Cell Growth Differ. 1991 Feb;2(2):67-76.

26.

Ordered splicing of thymidine kinase pre-mRNA during the S phase of the cell cycle.

Gudas JM, Knight GB, Pardee AB.

Mol Cell Biol. 1990 Oct;10(10):5591-5.

27.

Coordinate control of S phase onset and thymidine kinase expression.

Knight GB, Gudas JM, Pardee AB.

Jpn J Cancer Res. 1989 Jun;80(6):493-8. Review. No abstract available.

28.

A third genetic locus affecting the Ah (dioxin) receptor.

Karenlampi SO, Legraverend C, Gudas JM, Carramanzana N, Hankinson O.

J Biol Chem. 1988 Jul 25;263(21):10111-7.

29.

Nuclear posttranscriptional processing of thymidine kinase mRNA at the onset of DNA synthesis.

Gudas JM, Knight GB, Pardee AB.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4705-9.

30.
31.
32.

Reversible inactivation of the Ah receptor associated with changes in intracellular ATP levels.

Gudas JM, Hankinson O.

J Cell Physiol. 1986 Sep;128(3):449-56.

PMID:
3018004
33.

Intracellular location of the Ah receptor.

Gudas JM, Karenlampi SO, Hankinson O.

J Cell Physiol. 1986 Sep;128(3):441-8.

PMID:
3018003
34.

Supplemental Content

Loading ...
Support Center